Actionable news
0
All posts from Actionable news
Actionable news in ENDP: Endo Health Solutions Inc.,

Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property

0

/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that the U.S. District Court for the Southern District of New York has issued an order upholding its August 2015 ruling in Endo's favor and confirming the Court's prior injunction against the manufacture or sale of the generic version of non-crush-resistant OPANA® ER currently offered by Actavis, the U.S. generics business of Allergan plc, and the additional approved but not yet marketed generic version of the product developed by Roxane Laboratories. In December 2012, Endo filed a patent infringement complaint against Actavis for patent infringement based on Actavis' sale of a non-crush-resistant generic version of OPANA® ER. In 2013, Endo filed suits against the following additional applicants for non-crush-resistant OPANA® ER: Par Pharmaceutical (now a subsidiary of Endo), Teva Pharmaceuticals, Mallinckrodt LLC, Sandoz, Roxane Laboratories and Ranbaxy Laboratories. The suits against Par Pharmaceutical and Mallinckrodt LLC were dismissed pursuant to settlements, and the suits against Teva Pharmaceuticals and Sandoz were dismissed based on those...


More